BR112016013138A2 - mistura de peptídeos - Google Patents
mistura de peptídeosInfo
- Publication number
- BR112016013138A2 BR112016013138A2 BR112016013138-0A BR112016013138A BR112016013138A2 BR 112016013138 A2 BR112016013138 A2 BR 112016013138A2 BR 112016013138 A BR112016013138 A BR 112016013138A BR 112016013138 A2 BR112016013138 A2 BR 112016013138A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- peptide
- point mutation
- ras protein
- amino acid
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 230000035772 mutation Effects 0.000 abstract 3
- 102000016914 ras Proteins Human genes 0.000 abstract 3
- 108010014186 ras Proteins Proteins 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13196333 | 2013-12-09 | ||
| EP13196333.2 | 2013-12-09 | ||
| PCT/EP2014/077033 WO2015086590A2 (en) | 2013-12-09 | 2014-12-09 | A peptide mixture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016013138A2 true BR112016013138A2 (pt) | 2018-01-16 |
Family
ID=49765823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016013138-0A BR112016013138A2 (pt) | 2013-12-09 | 2014-12-09 | mistura de peptídeos |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9775892B2 (https=) |
| EP (5) | EP3369432A1 (https=) |
| JP (2) | JP6781403B2 (https=) |
| KR (1) | KR20160097290A (https=) |
| CN (1) | CN105980403A (https=) |
| AU (2) | AU2014363643B2 (https=) |
| BR (1) | BR112016013138A2 (https=) |
| CA (1) | CA2933126A1 (https=) |
| CL (4) | CL2016001405A1 (https=) |
| CY (1) | CY1120578T1 (https=) |
| DK (1) | DK3079715T3 (https=) |
| ES (1) | ES2682038T3 (https=) |
| HR (1) | HRP20181213T1 (https=) |
| HU (1) | HUE039840T2 (https=) |
| IL (1) | IL246007B2 (https=) |
| LT (1) | LT3079715T (https=) |
| MX (1) | MX2016007429A (https=) |
| PL (1) | PL3079715T3 (https=) |
| PT (1) | PT3079715T (https=) |
| RS (1) | RS57623B1 (https=) |
| RU (1) | RU2016127327A (https=) |
| SG (2) | SG11201604644QA (https=) |
| SI (1) | SI3079715T1 (https=) |
| WO (1) | WO2015086590A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3369432A1 (en) | 2013-12-09 | 2018-09-05 | Targovax Asa | A peptide mixture |
| CA2947963A1 (en) | 2014-05-06 | 2015-11-12 | Targovax Asa | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
| JP2020514321A (ja) | 2017-02-01 | 2020-05-21 | モデルナティーエックス， インコーポレイテッド | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
| WO2018232467A1 (en) * | 2017-06-22 | 2018-12-27 | The Westmead Institute for Medical Research | Adoptive t cell therapy 2 |
| BR112020025764A2 (pt) * | 2018-06-19 | 2021-05-11 | Biontech Us Inc. | neoantígenos e usos dos mesmos |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| MX2021001938A (es) * | 2018-08-22 | 2021-04-19 | Fred Hutchinson Cancer Center | Inmunoterapia dirigida a antigenos kras o her2. |
| WO2020172332A1 (en) | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| CA3132028A1 (en) * | 2019-03-30 | 2020-10-08 | Biontech Us Inc. | Compositions and methods for preparing t cell compositions and uses thereof |
| WO2021009633A1 (en) * | 2019-07-12 | 2021-01-21 | Massey University | Synthetic chromatin vaccine |
| US12453774B2 (en) | 2019-11-07 | 2025-10-28 | Genoimmune Therapeutics Co., Ltd. | Tumor immunotherapy polypeptide and application thereof |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| KR102515083B1 (ko) | 2020-12-24 | 2023-03-29 | 부산대학교 산학협력단 | 폴더블 페로브스카이트 태양전지 및 이의 제조 방법 |
| WO2022171032A1 (zh) * | 2021-02-10 | 2022-08-18 | 上海吉倍生物技术有限公司 | Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| WO2023220434A2 (en) * | 2022-05-12 | 2023-11-16 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
| US20250332239A1 (en) * | 2022-11-22 | 2025-10-30 | Elixirgen Therapeutics, Inc. | Antigens for cancer immunotherapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| CN102370974B (zh) | 2002-12-16 | 2014-09-17 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| PL1760089T3 (pl) | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| BRPI0709340A2 (pt) * | 2006-03-27 | 2013-04-16 | Globeimmune, Inc. | mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| EP3369432A1 (en) | 2013-12-09 | 2018-09-05 | Targovax Asa | A peptide mixture |
| CA2947963A1 (en) | 2014-05-06 | 2015-11-12 | Targovax Asa | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
-
2014
- 2014-12-09 EP EP18166278.4A patent/EP3369432A1/en not_active Withdrawn
- 2014-12-09 PT PT148281488T patent/PT3079715T/pt unknown
- 2014-12-09 SG SG11201604644QA patent/SG11201604644QA/en unknown
- 2014-12-09 KR KR1020167018341A patent/KR20160097290A/ko not_active Withdrawn
- 2014-12-09 RS RS20180907A patent/RS57623B1/sr unknown
- 2014-12-09 SI SI201430776T patent/SI3079715T1/en unknown
- 2014-12-09 SG SG10201811172PA patent/SG10201811172PA/en unknown
- 2014-12-09 BR BR112016013138-0A patent/BR112016013138A2/pt not_active Application Discontinuation
- 2014-12-09 ES ES14828148.8T patent/ES2682038T3/es active Active
- 2014-12-09 MX MX2016007429A patent/MX2016007429A/es unknown
- 2014-12-09 WO PCT/EP2014/077033 patent/WO2015086590A2/en not_active Ceased
- 2014-12-09 US US15/102,681 patent/US9775892B2/en not_active Expired - Fee Related
- 2014-12-09 DK DK14828148.8T patent/DK3079715T3/en active
- 2014-12-09 PL PL14828148T patent/PL3079715T3/pl unknown
- 2014-12-09 HR HRP20181213TT patent/HRP20181213T1/hr unknown
- 2014-12-09 EP EP14828148.8A patent/EP3079715B1/en active Active
- 2014-12-09 RU RU2016127327A patent/RU2016127327A/ru not_active Application Discontinuation
- 2014-12-09 JP JP2016557194A patent/JP6781403B2/ja active Active
- 2014-12-09 LT LTEP14828148.8T patent/LT3079715T/lt unknown
- 2014-12-09 CA CA2933126A patent/CA2933126A1/en not_active Abandoned
- 2014-12-09 AU AU2014363643A patent/AU2014363643B2/en not_active Ceased
- 2014-12-09 EP EP18164079.8A patent/EP3357505A1/en not_active Withdrawn
- 2014-12-09 HU HUE14828148A patent/HUE039840T2/hu unknown
- 2014-12-09 EP EP18166281.8A patent/EP3363458A3/en not_active Withdrawn
- 2014-12-09 CN CN201480074531.3A patent/CN105980403A/zh active Pending
- 2014-12-09 EP EP18166279.2A patent/EP3363457A1/en not_active Withdrawn
-
2016
- 2016-06-02 IL IL246007A patent/IL246007B2/en unknown
- 2016-06-08 CL CL2016001405A patent/CL2016001405A1/es unknown
-
2017
- 2017-03-17 US US15/461,837 patent/US10335473B2/en active Active
- 2017-08-02 US US15/667,288 patent/US10456457B2/en active Active
- 2017-09-27 US US15/716,861 patent/US10596239B2/en active Active
-
2018
- 2018-01-26 CL CL2018000226A patent/CL2018000226A1/es unknown
- 2018-01-26 CL CL2018000232A patent/CL2018000232A1/es unknown
- 2018-01-26 CL CL2018000238A patent/CL2018000238A1/es unknown
- 2018-08-10 CY CY20181100846T patent/CY1120578T1/el unknown
-
2019
- 2019-03-20 AU AU2019201937A patent/AU2019201937B2/en not_active Ceased
- 2019-10-04 JP JP2019183442A patent/JP2020023525A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016013138A2 (pt) | mistura de peptídeos | |
| BR112017025728A2 (pt) | fragmentos mutantes da proteína ras | |
| BR112019010699A2 (pt) | receptores de células t e imunoterapia empregando os mesmos | |
| BR112019008351A2 (pt) | imunoglobulinas e usos das mesmas | |
| BR112017001940A2 (pt) | proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| BR112015032875A2 (pt) | derivados de peptídeos do tipo glp-1, e usos dos mesmos | |
| BR112017024797A2 (pt) | neoantígenos partilhados | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| BR112017015833A2 (pt) | compostos anti-senescência e usos dos mesmos | |
| BR112017001860A2 (pt) | peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal | |
| BR112019004189A2 (pt) | trímeros estabilizados da região de tronco da hemaglutinina do vírus influenza grupo 2 e usos dos mesmos | |
| CY1121332T1 (el) | Μiμhtiκα καλσιτονινης προς θεραπεια ασθενειων και διαταραχων | |
| BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
| BR112014024751A2 (pt) | antígenos de clostridium difficile | |
| BR122020006914B8 (pt) | Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| BR112018075032A2 (pt) | proteínas de hemaglutinina do vírus influenza e seus uso | |
| BR112013008407A2 (pt) | antígenos de clostridium difficile | |
| BR112017003472A2 (pt) | anticorpos, fragmento fab de anticorpo e método para o tratamento de uma doença inflamatória | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| BR112016024494A8 (pt) | análogo de peptídeo e seu uso | |
| BR112017008525A2 (pt) | proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo. | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |